A Phase II Study to Determine the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution on Myopia Control in Subjects Aged 3-12 Years.
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs SHJ 002 (Primary) ; SHJ 002 (Primary) ; Atropine
- Indications Corneal disorders; Dry eyes
- Focus Therapeutic Use
- Sponsors Sunhawk Vision Biotech
- 07 Jan 2025 Planned initiation date changed from 1 Aug 2024 to 1 Jan 2025.
- 07 Jan 2025 Status changed from not yet recruiting to recruiting.
- 03 Sep 2024 New trial record